The MarketReader Minute
π Moderna Tumbles on Lower Sales Forecast, Neurocrine Biosciences Beats Expectations, Vericel and MiMedx Slide | Biotech Sector Insights
Regeneron Pharmaceuticals exceeded earnings and revenue estimates, benefiting from strong Dupixent sales but facing weaker Libtayo sales. In contrast, Biogen raised its fiscal year 2024 guidance and reported strong Q2 results.